On August 25, 2025 Eli Lilly and Company (NYSE:LLY) reported it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m., Eastern time (Press release, Eli Lilly, AUG 25, 2025, View Source [SID1234655456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On August 25, 2025 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) reported its interim results for the period ending June 30, 2025, along with updates on recent achievements (Press release, Antengene, AUG 25, 2025, View Source [SID1234655472]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ATG-022 (CLDN18.2 ADC) has shown promising results in the ongoing Phase I/II CLINCH study, demonstrating robust efficacy and a favorable safety profile in gastric/GEJ adenocarcinoma across high, low, and ultra-low CLDN18.2 expression levels.

In moderate-to-high expressors (IHC 2+ >20%), the 2.4 mg/kg cohort achieved a 40% ORR (12/30, including 1 CR), a 90% DCR, 6.97 months of mPFS, with 6-month PFS at 51.1%, 9-month OS at 82.7%, and 12-month OS at 66.2%; the 1.8 mg/kg cohort achieved 40% ORR (10/25, including 1 CR) and 84% DCR. In low/ultra-low expressors (IHC 2+ ≤20%) treated at 1.8–2.4 mg/kg, ATG-022 achieved 33.3% ORR (6/18, including 1 CR) with 50% DCR.

Both dose cohorts were well tolerated, with no ophthalmologic toxicities or interstitial lung disease observed, and the 1.8 mg/kg dose showing particularly low rates of Grade ≥3 TRAEs

In a basket cohort of CLDN18.2-positive tumors, preliminary data showed tumor shrinkage in all 7 evaluable patients with a subtype of gynecologic cancer.

ATG-022 has also been granted Breakthrough Therapy Designation by China’s NMPA for the treatment of CLDN18.2-positive, HER2-negative, unresectable or metastatic gastric/GEJ adenocarcinoma after at least two prior therapies.
Antengene is advancing a broad development strategy in gastric cancer, including first-line ATG-022 with pembrolizumab and CAPOX/FOLFOX, second-line ATG-022 with pembrolizumab, and third-line ATG-022 monotherapy.

ATG-037 (oral CD73 small molecule inhibitor) showed robust efficacy in the Phase I/II STAMINA study. In the CPI-resistant melanoma subgroup, results were particularly encouraging, with 36.4% ORR and 100% DCR (1CR, 3PRs), in patients largely double-resistant to both anti-PD-1 and anti-CTLA-4 antibodies. Responses were durable, with the CR patient remaining on treatment for over 32 months, 2 PR patients for more than 15 months, and 1 SD patient for over 28 months. In the CPI-resistant NSCLC subgroup, ATG-037 achieved a 21.4% ORR and 71.4% DCR (3 PRs).

AnTenGager Platform is Antengene’s next-generation T-cell engager technology, featuring "2+1" bivalent binding, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to reduce CRS and improve efficacy. Broadly applicable across autoimmune diseases, solid tumors, and hematologic malignancies, the platform is open to global partnerships. ATG-201 (CD19 x CD3), the lead TCE program, expands Antengene’s pipeline into autoimmune diseases. Preclinical studies in non-human primates showed repeated dosing at 1mpk, 3mpk, and 6mpk was well tolerated with very low cytokine release, and the surrogate antibody mediated complete B-cell depletion in blood, spleen, and lymph nodes. ATG-201 is expected to enter clinical development in Q4 2025.

To learn more about the 2025 interim financial results, please see the full announcement in the "Investor Relations" section on the company’s website.

On August 25, 2025 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons (Press release, Hutchison China MediTech, AUG 25, 2025, View Source [SID1234655457]). In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recovery. We thank Mr Cheng for his agreement to assume responsibility for overseeing the day-to-day operations and management of the Company during this interim period. The board has full confidence in Mr. Cheng’s capabilities to lead the Company. The Board is confident that all research, development and commercial initiatives will remain on track."

Dr Weiguo Su, Executive Director, said, "This has been a very difficult decision to make, but at this time my focus must be on my health. I am certain that the Board, Mr Cheng and everyone at HUTCHMED will ensure the continued execution of our strategy and that the scientific team will continue its work on the determined drug research and discovery pipeline as planned. I would like to thank everyone for their support and look forward to being able to return to work as soon as possible.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said, "Over the last 20 years under Dr Su’s leadership and the contribution of the entire team, HUTCHMED has built a portfolio of drugs and a strategy to successfully build new platforms and capabilities to deliver additional value. Together with our management team we shall endeavor to ensure on-track delivery. My best wishes to Dr Su for a speedy recovery."

On August 25, 2025 Varian, a Siemens Healthineers company, reported the successful completion of enrollment and treatment in its FAST-02 (Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax) clinical trial (Press release, Varian Medical Systems, AUG 25, 2025, View Source [SID1234655473]). The FAST-02 study targets painful bone metastases in the thoracic region and represents a significant step toward bringing this investigational radiotherapy treatment into clinical practice.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial was conducted at Cincinnati Children’s Hospital/UC Health Proton Therapy Center and enrolled 10 participants. It focused on evaluating treatment-related side effects and the efficacy of treatment, which was assessed using trial participants’ reported pain relief. FAST-02 builds upon findings from Varian’s FAST-01 trial, which evaluated clinical workflow feasibility of Flash therapy and treatment-related side effects for participants with bone metastases in the extremities. The trial is led by Principal Investigator John Perentesis, M.D., Professor and Director, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital, and lead Co-Investigator Emily Daugherty, M.D., Associate Professor of Radiation Oncology, University of Cincinnati Cancer Center.

Flash therapy delivers treatment at ultra-high dose rates in typically less than one second – over 100 times faster than conventional radiation therapy—and has demonstrated potential in preclinical studies to reduce damage to surrounding healthy tissues while maintaining effective tumor control.

"Completing treatments for FAST-02 is a pivotal and progressive step in our effort to establish the safety and effectiveness of Flash radiotherapy," said John Perentesis, M.D., Professor and Director, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital Medical Center (CCHMC). "This trial helps lay the groundwork needed to move Flash into more advanced clinical settings—an innovation that could redefine radiation oncology and meaningfully improve patient outcomes."

As part of the FAST-02 trial, Varian’s ProBeam proton therapy system was modified to enable ultra-high dose rate delivery for Flash treatments. In parallel, the Eclipse treatment planning system was enhanced to support planning for Flash therapy. Varian is advancing Flash therapy as an integrated system, encompassing planning, quality assurance, and treatment delivery technologies.

"The integration of treatment and planning represents a major technological achievement," said Anthony Mascia, executive director and director of medical physics of the CCHMC Proton Therapy Center. "From a physics standpoint, we’re pushing the boundaries of both planning and delivering ultra-high dose rates, and we’re doing it safely."

OSF HealthCare, a multi-site healthcare system with locations across Illinois and Michigan, collaborated in the trial and referred participants for enrollment.

James McGee, MD, founding director of the OSF Cancer Institute, stated: "We’re proud to have supported the FAST-02 trial. It is rewarding to contribute to research that further advances Flash therapy."

Added Deepak "Dee" Khuntia, MD, senior vice president and chief medical officer at Varian: "This is an exciting time for radiation oncology; completing enrollment in FAST-02 underscores our commitment to develop the evidence needed to advance technologies that have the potential to transform the future of cancer care. We are proud to collaborate with institutions that share our vision for patient-centered innovation."

Now that participant treatment is complete, data analysis of the results will inform future clinical studies and further evaluation of the potential of Flash therapy across broader treatment applications.

For information about the FAST-02 clinical trial, go to: Study Details | FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax | ClinicalTrials.gov

On August 25, 2025 iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, reported the closing of its previously announced underwritten public offering of the securities described below for initial gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses (Press release, iBioPharma, AUG 25, 2025, View Source [SID1234655458]). In addition, if all of the Series G Warrants and Series H Warrants are exercised in full for cash, iBio would receive additional gross proceeds of $50 million, before deducting expenses and fees, for total gross proceeds of $100 million before deducting underwriting discounts and commissions and offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.

Overview of Pre-Funded Warrants and Common Stock Warrants

In connection with the offering, iBio issued (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase 71,540,000 shares of iBio’s common stock, and (ii) accompanying Series G warrants (the "Series G Warrants") representing the right to purchase (a) 35,770,000 shares of iBio’s common stock, or pre-funded warrants in lieu thereof, and (b) Series H warrants (the "Series H Warrants") representing the right to purchase 35,770,000 shares of iBio’s common stock, or pre-funded warrants in lieu thereof. The combined public offering price of one Pre-Funded Warrant and one Series G Warrant to purchase (i) one-half of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, and (ii) one Series G Warrant to purchase one-half of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, was $0.699.

The Pre-Funded Warrants are, and the pre-funded warrants issuable upon exercise of the Series G Warrants and Series H Warrants will be, immediately exercisable and exercisable until exercised in full. The Series G Warrants and Series H Warrants are immediately exercisable from their date of issuance and have an exercise price equal to $0.70 per share of iBio’s common stock (or $0.699 per pre-funded warrant) and in the case of the Series G Warrants, the accompanying Series H Warrant. The Series G Warrants will expire on the date that is the earlier of (i) 30 trading days following iBio’s public announcement, via a press release on a nationally recognized news wire or the filing of a Current Report on Form 8-K with the Securities and Exchange Commission (the "SEC"), that an Investigational New Drug Application ("IND") filed with the U.S. Food and Drug Administration, a Clinical Trial Notification filed with the applicable foreign governmental body in Australia, a Clinical Trial Application filed with the European Medicines Agency, or an equivalent submission filed with a foreign governmental body to initiate a clinical trial in any other foreign jurisdiction has been accepted or has otherwise gone into effect, as applicable (such public filing or announcement, the "Trial Initiation Milestone") and (ii) five years from the date of issuance. In addition, each Series G Warrant will immediately expire in proportion to the extent that the corresponding Pre-Funded Warrant held by a holder is exercised prior to the occurrence of the Trial Initiation Milestone (solely to the extent the proportion of the unexercised portion of the Series G Warrant relative to the originally issued Series G Warrant is greater than the proportion of the unexercised portion of the Pre-Funded Warrant relative to the originally issued Pre-Funded Warrant). When issued upon exercise of the Series G Warrants, the Series H Warrants will expire on the four-year anniversary of the closing date of the offering.

iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, the myostatin and activin A bispecific, and IBIO-600 programs, through key development milestones, as well as to continue to progress its other preclinical pipeline assets, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes.

Leerink Partners acted as the lead bookrunner for the offering. LifeSci Capital and Oppenheimer & Co. acted as bookrunning managers. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as financial advisor to iBio.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.